Oreste Gentilini1, Edoardo Botteri2, Maria Cristina Leonardi3, Nicole Rotmensz2, Jose Vila4, Nickolas Peradze4, Maria Virginia Thomazini4, Barbara Alicja Jereczek5, Viviana Galimberti4, Alberto Luini4, Paolo Veronesi6, Roberto Orecchia7. 1. Breast Surgery Division, European Institute of Oncology, Milano, Italy. Electronic address: gentilini.oreste@hsr.it. 2. Epidemiology and Biostatistics Division, European Institute of Oncology, Milano, Italy. 3. Radiotherapy Division, European Institute of Oncology, Milano, Italy. 4. Breast Surgery Division, European Institute of Oncology, Milano, Italy. 5. Radiotherapy Division, European Institute of Oncology, Milano, Italy; University of Milan, European Institute of Oncology, Italy. 6. Breast Surgery Division, European Institute of Oncology, Milano, Italy; Epidemiology and Biostatistics Division, European Institute of Oncology, Milano, Italy; Radiotherapy Division, European Institute of Oncology, Milano, Italy; University of Milan, European Institute of Oncology, Italy. 7. Scientific Directorate, European Institute of Oncology, Milano, Italy; University of Milan, European Institute of Oncology, Italy.
Abstract
BACKGROUND AND PURPOSE: Whole breast radiotherapy (WBRT) is one of the possible reasons for the low rate of axillary recurrence after breast-conserving surgery (BCS). PATIENTS AND METHODS: We retrospectively collected data from 4,129 consecutive patients with breast cancer ⩽2cm and negative sentinel lymph node who underwent BCS between 1997 and 2007. We compared the risk of axillary lymph node recurrence between patients treated by WBRT (n=2939) and patients who received partial breast irradiation (PBI; n=1,190) performed by a single dose of electron intraoperative radiotherapy. RESULTS: Median tumour diameter was 1.1cm in both WBRT and PBI. Women who received WBRT were significantly younger and expressed significantly more multifocality, extensive in situ component, negative oestrogen receptor status and HER2 over-expression than women who received PBI. After a median follow-up of 8.3years, 37 and 28 axillary recurrences were observed in the WBRT and PBI arm, respectively, corresponding to a 10-year cumulative incidence of 1.3% and 4.0% (P<0.001). Multivariate analysis resulted in a hazard ratio of 0.30 (95% CI 0.17-0.51) in favour of WBRT. CONCLUSIONS: In this large series of women with T1 breast cancer and negative sentinel lymph node treated by BCS, WBRT lowered the risk of axillary recurrence by two thirds as compared to PBI.
BACKGROUND AND PURPOSE: Whole breast radiotherapy (WBRT) is one of the possible reasons for the low rate of axillary recurrence after breast-conserving surgery (BCS). PATIENTS AND METHODS: We retrospectively collected data from 4,129 consecutive patients with breast cancer ⩽2cm and negative sentinel lymph node who underwent BCS between 1997 and 2007. We compared the risk of axillary lymph node recurrence between patients treated by WBRT (n=2939) and patients who received partial breast irradiation (PBI; n=1,190) performed by a single dose of electron intraoperative radiotherapy. RESULTS: Median tumour diameter was 1.1cm in both WBRT and PBI. Women who received WBRT were significantly younger and expressed significantly more multifocality, extensive in situ component, negative oestrogen receptor status and HER2 over-expression than women who received PBI. After a median follow-up of 8.3years, 37 and 28 axillary recurrences were observed in the WBRT and PBI arm, respectively, corresponding to a 10-year cumulative incidence of 1.3% and 4.0% (P<0.001). Multivariate analysis resulted in a hazard ratio of 0.30 (95% CI 0.17-0.51) in favour of WBRT. CONCLUSIONS: In this large series of women with T1 breast cancer and negative sentinel lymph node treated by BCS, WBRT lowered the risk of axillary recurrence by two thirds as compared to PBI.
Authors: Jana de Boniface; Marcus Schmidt; Jutta Engel; Marjolein L Smidt; Birgitte Vrou Offersen; Toralf Reimer Journal: Breast Care (Basel) Date: 2018-09-05 Impact factor: 2.860
Authors: Maria Cristina Leonardi; Ida Rosalia Scognamiglio; Barbara Alicja Jereczek-Fossa; Giovanni Corso; Patrick Maisonneuve; Samantha Dicuonzo; Damaris Patricia Rojas; Maria Alessia Zerella; Anna Morra; Marianna Alessandra Gerardi; Mattia Zaffaroni; Alessandra De Scalzi; Antonia Girardi; Francesca Magnoni; Emilia Montagna; Cristiana Iuliana Fodor; Viviana Enrica Galimberti; Paolo Veronesi; Roberto Orecchia; Roberto Pacelli Journal: Breast Cancer Res Treat Date: 2021-04-27 Impact factor: 4.872
Authors: Gerd Fastner; Roland Reitsamer; Christoph Gaisberger; Markus Stana; Felix Sedlmayer Journal: Strahlenther Onkol Date: 2021-10-01 Impact factor: 3.621
Authors: Charlotte E Coles; Clare L Griffin; Anna M Kirby; Jenny Titley; Rajiv K Agrawal; Abdulla Alhasso; Indrani S Bhattacharya; Adrian M Brunt; Laura Ciurlionis; Charlie Chan; Ellen M Donovan; Marie A Emson; Adrian N Harnett; Joanne S Haviland; Penelope Hopwood; Monica L Jefford; Ronald Kaggwa; Elinor J Sawyer; Isabel Syndikus; Yat M Tsang; Duncan A Wheatley; Maggie Wilcox; John R Yarnold; Judith M Bliss Journal: Lancet Date: 2017-08-02 Impact factor: 79.321